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Introduction: Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes
are related to the level of expression of the proliferation pathway and intrinsic subtypes.
Methods: Expression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2),
epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed
from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four
biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14), luminal B (ER + and/or PR+, HER2−,
Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER−, PR−, HER2−, any Ki-67). Subtype
definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14, any CK 5/6, any EGFR),
luminal B (ER + and/or PR+, HER2−, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER−, PR−, HER2+, any Ki-67,
any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER−, PR−,
HER2−, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER−, PR−, HER2−, any Ki-67, CK 5/6−, EGFR−). Each
four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence
hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value.
Results: Luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady.
Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence
nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months
but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth
risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months.
Conclusions: Each intrinsic subtype has a particular pattern of relapses over time which change depending on the
level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both
on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients.* Correspondence: ealbac@uma.es
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The definition of the genomic intrinsic subtypes of
breast cancer has been established as the best explan-
ation for the heterogeneous patient outcomes [1-3]. In
their original paper, Perou et al. [1] found that the genes
that differ most between the intrinsic subtypes (luminal
A, luminal B, human epidermal growth factor receptor 2
(HER2)-enriched, basal-like and normal-like) were those
within the proliferation cluster. In this respect, a meta-
analysis of publicly available breast cancer gene expression
data, including those from several published prognostic
signatures, revealed that more than 70% of the genes
associated with patient survival were correlated with
the proliferation pathway, whereas 26% were related to
estrogen receptor (ER) signaling and 2% to ERBB2
amplification [4]. The expression of ESR1- and ERBB2-
related genes showed a bimodal distribution; however,
this pattern was not observed in proliferative genes. The
expression of genes related to proliferation was consti-
tutively high in ER−/HER2− and ER-/HER2+ tumors.
However, in ER+/HER2+ tumors, proliferation gene ex-
pression occurred along a continuum with a wide range of
values from low in relation to that of normal breast tissues
to the high values observed in ER−/HER2− or ER-/HER2+
tumors [4]. These data were corroborated by the same
group in a later analysis that included more than twice the
number of public breast cancer microarrays data sets [5],
contributing to the robustness of their findings.
Currently, the applicability of gene expression profiling
in clinical practice is extremely limited for technical and
economic reasons. Several studies have shown that breast
carcinomas can be stratified into subtypes with different
prognoses and treatment responses, similarly to those de-
fined by the genomic portraits, using a set of four [6-10]
or six [11-15] immunohistochemical markers, including
the assessment of a proliferation marker such as Ki-67 in
both definitions.
Together with classic prognostic factors, the intrinsic
subtype data provide information with which to appraise
the total recurrence risk for a given patient. In designing a
therapeutic strategy to prevent disease recurrence, how-
ever, it is necessary not only to know the total risk of re-
lapse but also likely to ascertain when recurrence is most
likely to occur and when the risk becomes minimal. This
knowledge could help to establish at what time the admin-
istration of adjuvant treatment will be more effective,
which should be taken into consideration when develop-
ing new adjuvant strategies. There are enough data on the
time-varying recurrence risk obtained through analysis
using hazard rate functions to support this decision-
making. Different authors have described the maximum
peak of recurrence risk at 12 to 24 months after surgery
[16-22] and the occurrence of a second peak at approxi-
mately the fifth year in some cases [17,18,20,22].In this study, we investigated the importance of the
proliferation pathway in the behavior of breast cancer
intrinsic subtypes using different statistical approaches.
We applied two intrinsic subtype definitions using a set
of four or six immunohistochemical markers in a series
of early breast cancer patients consecutively treated in a
single institution. We also divided every intrinsic sub-
type according to the level of expression of Ki-67, except
in luminal A and luminal B subtypes, because in these
cases the Ki-67 expression levels are low and high, re-
spectively, by definition. We hypothesized that a more
detailed analysis of the recurrence risk using a hazard
rate function methodology would be able to detect differ-
ences in such risk over time, depending on the level of
expression of the proliferation pathway, even in those
subtypes such as HER2-enriched or triple-negative.
Methods
Study population
Patients referred to our department were included pro-
spectively in a controlled database. A filtered search was
performed to identify stages I to III breast cancer pa-
tients enrolled from January 1982 to December 2008.
We identified 3,329 patients with stages I to III breast
cancer. Nearly 50% (n = 1,652) were referred from other
centers; consequently, no tumor samples were available.
We excluded 135 patients for various reasons, and,
among the remaining 1,542 patients, there were no rep-
resentative tumor samples in 293 cases (19%). Therefore,
1,249 patients were definitively included in the study
(Figure 1).
The patients were uniformly treated according to clin-
ical guidelines. Briefly, the chemotherapy regimens used
during the 1980s were cyclophosphamide, methotrexate
and fluorouracil (CMF); during the 1990s, they were
anthracycline-based; and thereafter therapy was anthra-
cycline plus taxane–based. Fifty-seven percent of the
patients received adjuvant chemotherapy (CMF, 27.4%;
anthracycline-based, 45.9%; taxanes with or without
anthracyclines, 25.1%; and unknown 1.6%). Endocrine
therapy was administered in 883 patients (luteinizing
hormone-releasing hormone analogues plus tamoxifen,
4.5%; tamoxifen, 66.9%; tamoxifen followed by aromatase
inhibitor, 19.6%; and aromatase inhibitor 8.9%). Eighteen
patients received adjuvant trastuzumab.
Patients underwent follow-up at 6-month intervals
during the first 4 years and annually thereafter. Clinico-
pathological and follow-up information was obtained by
chart review.
The study was approved by the Hospital Universitario
Virgen de la Victoria Clinical Research Ethics Commit-
tee and by the Fondo de Investigaciones Sanitarias from
the Ministry of Science and Innovation of Spain under
the title “Study of time distribution of recurrence for
3,329 newly patients included as stage I-III breast 
cancer  in a database of our Department of 
Medical Oncology from Jan 1982 to Dec 2008
1,652 patients who had surgery in 
other center without tumor samples 
available were excluded 
38 patients with DCIS only were 
excluded
15 patients with metastatic disease 
at diagnosis were excluded
293 patients with no representative 
tumor samples were excluded
62 patients who received 
neoadjuvant chemotherapy were 
excluded
7 patients without axillary dissection 
were excluded
10 patients with bilateral tumors 
were excluded
3 patients diagnosed previously with 
other cancer was excluded
1,249 stage I-III breast cancer patients with 
representative tumor samples available were 
included
Figure 1 Flow diagram of the patients through the study. DCIS, ductal carcinoma in situ.
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consent was obtained from patients whose data have
been included in this study, except in those cases where
the patient had died, in which event the mentioned
ethics committees waived the need to obtain informed
consent.
Tissue microarrays and immunohistochemistry
Archival tumor specimens were retrieved, and hematoxylin
and eosin sections from each block were reviewed by a
pathologist to select representative tumor tissue areas.
Tissue microarrays were constructed, and the cases
were represented in triplicate with samples from 0.6-mm
cores. Immunohistochemical staining was performed for
ER (clone SP1; Master Diagnóstica, Granada, Spain),
progesterone receptor (PR) (clone Y85; Master Diagnóstica),
human epidermal growth factor receptor 2 (HER2)
(HercepTest; Dako, Glostrup, Denmark), Ki-67 (clone
SP6; Master Diagnóstica), epidermal growth factorreceptor (EGFR) (clone EP38Y; Master Diagnóstica)
and cytokeratin types 5 and 6 (CK5/6) (clone D5/16B4;
Master Diagnóstica). Staining and interpretation of ER,
PR, HER2, Ki-67, EGFR and CK5/6 were performed as
previously described [23-26]. ER and PR positivity were
defined as immunostaining of more than 1% of tumor nu-
clei. Tumors were considered positive for HER2 if immu-
nostaining was scored as 3+ according to HercepTest
criteria. All cases with ambiguous expression of HER2
(HercepTest score 2+) were evaluated by chromogenic in
situ hybridization (CISH), and an amplification ratio of 2.0
or more was considered as a positive result (HER2 CISH
pharmDx; Dako). Ki-67 was visually scored for percentage
of tumor cell nuclei with positive immunostaining above
the background level. EGFR and CK5/6 stains were con-
sidered positive if any (weak or strong) cytoplasmic and/
or membranous invasive carcinoma cell staining was ob-
served. Tissue microarrays were scored by two patholo-
gists blinded to the clinicopathological characteristics and
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each of the biomarkers analyzed and the categorization of
intrinsic subtypes according to the four or six immunohis-
tochemical variables are summarized in Table 1. The
Ki-67 cutoff used was that defined by Cheang et al. [12].Statistical analysis methods
The variables analyzed included age, tumor size, histo-
logical grade, lymph node status, local therapy, adminis-
tration of adjuvant chemotherapy, use of adjuvant
hormone therapy and intrinsic subtype defined by the
four or six biomarkers. The endpoint was breast cancer–
free survival (BCFS), defined as the time from surgery
until a local, regional or distant recurrence, a second
contralateral tumor or death from breast cancer, which-
ever occurred first. Patients without relapse or who were
lost to follow-up were censored at the last follow-up. Pa-
tients who died as a result of any cause other than breast
cancer were censored at the time of death. All statistical
analyses were performed using R version 2.14.0 software
[27]. (Last accessed April 29th, 2013).
For a more in-depth analysis regarding the import-
ance of the proliferation pathway in the behavior of the
intrinsic subtypes of breast cancer, we divided each
subtype into two groups: with Ki-67 <14% or with Ki-
67 ≥14%. The χ2 test was used to compare the distribution
of the baseline characteristics among the subgroups. An
actuarial survival was performed using the Kaplan-Meier
method, and the differences were assessed with logrank,
Tarone-Ware and Peto-Peto tests.Table 1 Immunohistochemical definition of breast cancer intr
Definition and
subtype ER PR HER2
Definition of
positive result




Luminal A ER + or PR+ Negati
Luminal B ER + or PR+ Negati
HER2-enriched Any Any Positiv
Triple-negative Negative Negative Negati
Subtype 6 biomarkers
Luminal A ER + or PR+ Negati
Luminal B ER + or PR+ Negati
Luminal HER2 ER + or PR+ Positiv
HER2-enriched Negative Negative Positiv
Basal-like Negative Negative Negati
TNP nonbasal Negative Negative Negati
aCISH, chromogenic in situ hybridization; CK, cytokeratin; EGFR, epidermal growth fa
receptor 2; PR, progesterone receptor; TNP, triple-negative phenotype.The relationships between the various prognostic fac-
tors and BCFS were assessed using a Cox proportional
hazard regression. Only cases with information for all
covariates were included in this analysis (n = 1,215). A
variable selection was performed using backward and
forward stepwise selection processes (the significance
level for entry and permanence of a given variable in the
model was P < 0.05). Among the different candidate Cox
models used to analyze the data, the preferred final
model was the one with the minimum Akaike informa-
tion criterion value [28]. The assumption of hazard pro-
portionality for the model was tested, verifying that the
prognostic effect of each covariate was proportional
throughout the entire follow-up; that is, the effects did
not vary over time. A P-value less than 0.05 indicated a
violation of the proportional hazards assumption. If the
assumption of proportional hazards is rejected, it is ne-
cessary to study the changes of recurrence risk rates
over time. These hazard functions are estimated from
right-censored data using kernel-based methods with a
global bandwidth selection algorithm and boundary ker-
nel formulations [29]. Afterward it was confirmed that a
smoothed hazard function provided a realistic estimation
of the underlying hazard function. The results are pre-
sented in accordance with the Reporting Recommenda-
tions for Tumor Marker prognostic studies [30].
Results
Patient cohort
In the final cohort of 1,249 patients, the median follow-











ve Negative – –
ve Positive – –
e Any – –
ve Any – –
ve Negative Any Any
ve Positive Any Any
e Any Any Any
e Any Any Any
ve Any CK5/6-positive EGFR-positive
ve Any Negative Negative
ctor receptor; ER, estrogen receptor; HER2, human epidermal growth factor
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locoregional recurrence in 64 cases and contralateral tu-
mors in 8 cases.
Clinicopathological characteristics of the patients with
intrinsic subtypes defined by the four biomarkers areTable 2 Patient characteristics for breast cancer intrinsic subt





(N = 376) Pb
Ki-67
(N =
Age (years), n (%)
<40 33 (6.1) 32 (8.5) NS 4 (9
40 to 55 197 (36.5) 139 (37.1) 14 (3
>55 310 (57.3) 205 (54.4) 24 (5
Menopausal status, n (%)
Premenopausal 172 (31.9) 130 (34.7) NS 15 (3
Postmenopausal 360 (66.6) 242 (64.3) 26 (6
NA 8 (1.5) 4 (1.1) 1 (2
Tumor size (cm), n (%)
<2 250 (46.4) 158 (42.1) NS 14 (3
2 to 5 261 (48.2) 198 (52.5) 23 (5
>5 22 (4.1) 14 (3.7) 4 (9
NA 7 (1.3) 6 (1.6) 1 (2
Tumor grade, n (%)
1 144 (26.7) 39 (10.4) <0.0001 2 (4
2 311 (57.5) 226 (60.0) 27 (6
3 47 (8.7) 91 (24.3) 10 (2
NA 38 (7.1) 20 (5.3) 3 (7
Lymph nodes, n (%)
0 293 (54.2) 192 (50.9) NS 15 (3
1 to 3 145 (26.9) 109 (29.1) 16 (3
≥4 101 (18.7) 73 (19.5) 11 (2
NA 1 (0.2) 2 (0.5) –
Chemotherapy, n (%)
No 275 (50.8) 174 (46.1) NS 10 (2
Yes 260 (48.2) 199 (53.1) 31 (7
NA 5 (0.9) 3 (0.8) 1 (2
Hormonotherapy, n (%)
No 106 (19.5) 67 (17.6) NS 22 (5
Yes 432 (80.1) 307 (81.9) 20 (4
NA 2 (0.4) 2 (0.5) –
Local therapy, n (%)
Mastectomy alone 172 (31.9) 105 (28.0) 19 (4
Mastectomy + RT 61 (11.3) 36 (9.6) NS 7 (1
Lumpectomy alone 28 (5.2) 13 (3.5) 1 (2
Lumpectomy + RT 279 (51.6) 222 (58.9) 15 (3
aHER2, human epidermal growth factor receptor 2; NA, not available; NS, not signifi
with Ki-67 were not available. dOne case with Ki-67 was not available.shown in Table 2 and those defined by the six bio-
markers are given in Table 3. The most frequent intrin-
sic subtype was luminal A (43.2%), followed by luminal
B (30.1%), triple-negative (14.6%) and HER2-enriched
(12.1%). Using the six-biomarker definition, there wereypes defined by four biomarkersa








(N = 143)d Pb
.5) 15 (14.0) NS 5 (13.2) 22 (15.4) NS
3.3) 49 (45.8) 9 (23.7) 58 (40.6)
7.1) 43 (40.2) 24 (63.2) 63 (44.1)
5.7) 53 (49.5) NS 12 (31.6) 59 (41.3) NS
1.9) 54 (50.5) 26 (68.4) 83 (58.0)
.4) – – 1 (0.7)
3.3) 29 (27.1) NS 8 (21.1) 36 (25.2) NS
4.8) 67 (62.6) 27 (71.1) 89 (62.2)
.5) 10 (9.3) 1 (2.6) 13 (9.1)
.4) 1 (0.9) 2 (5.3) 5 (3.5)
.8) 2 (1.9) 0.0036 1 (2.6) 1 (0.7) 0.003
4.3) 43 (40.2) 19 (50.0) 38 (26.6)
3.8) 55 (51.4) 13 (34.2) 90 (62.9)
.1) 7 (6.5) 5 (13.2) 14 (9.8)
5.7) 48 (44.9) NS 13 (34.2) 77 (53.8) NS
8.1) 28 (26.2) 13 (34.2) 36 (25.2)
6.2) 30 (28.0) 11 (28.9) 27 (18.9)
1 (0.9) 1 (2.6) 3 (2.1)
3.8) 27 (25.2) NS 9 (23.7) 20 (14.0) NS
3.8) 79 (73.8) 29 (76.3) 121 (84.6)
.4) 1 (0.9) – 2 (1.4)
2.4) 45 (42.1) NS 19 (50.0) 100 (69.9) NS
7.6) 62 (57.9) 19 (50.0) 43 (30.1)
– – –
5.2) 30 (28.0) 20 (52.6) 36 (25.2)
6.7) 16 (15.0) NS 7 (18.4) 23 (16.1) NS
.4) 8 (7.5) – 5 (3.5)
5.7) 53 (49.5) 11 (28.9) 79 (55.2)
cant; RT, radiotherapy. bP values were calculated using the χ2 test. cTwo cases
Table 3 Patient characteristics for breast cancer intrinsic subtypes defined by six biomarkersa
Characteristics
Luminal A and luminal B
(N = 916)




















(N = 23)d Pb
Age (years), n (%)
<40 33 (6.1) 32 (8.5) NS 2 (11.1) 10 (17.5) NS 2 (8.3) 5 (10.0) NS 1 (7.7) 15.0) NS 4 (16.0) 4 (17.4) NS
40 to 55 197 (36.5) 139 (37.1) 5 (27.8) 24 (42.1) 9 (37.5) 25 (50.0) 3 (23.1) 39.2) 6 (24.0) 11 (47.8)
>55 310 (57.3) 205 (54.4) 11 (61.1) 23 (40.4) 13 (54.2) 20 (40.0) 9 (69.2) 45.8) 15 (60.0) 8 (34.8)
Menopausal status, n (%)
Premenopausal 172 (31.9) 130 (34.7) NS 6 (33.3) 25 (43.9) NS 9 (37.5) 28 (56.0) NS 4 (30.8) 41.7) NS 8 (32.0) 9 (39.1) NS
Postmenopausal 360 (66.6) 242 (64.3) 11 (61.1) 32 (56.1) 15 (62.5) 22 (44.0) 9 (69.2) 58.3) 17 (68.0) 13 (56.5)
NA 8 (1.5) 4 (1.1) 1 (5.6) – – – – – – 1 (4.3)
Tumor size (cm), n (%)
<2 250 (46.4) 158 (42.1) NS 8 (44.2) 18 (31.6) NS 6 (25.0) 11 (22.0) NS 2 (15.4) (25) NS 6 (24.0) 6 (26.1) NS
2 to 5 261 (48.2) 198 (52.5) 9 (50.0) 36 (63.2) 14 (58.3) 31 (62.0) 10 (76.9) 64.2) 17 (68.0) 12 (52.2)
>5 22 (4.1) 14 (3.7) – 3 (5.3) 45 (16.7) 7 (14.0) – 6.7) 1 (4.0) 5 (21.7)
NA 7 (1.3) 6 (1.6) 1 (5.6) – – 1 (2.0) 1 (7.7) 4.2) 1(4.0) –
Tumor grade, n (%)
1 144 (26.7) 39 (10.4) <.0001 1 (5.9) 2 (3.8) .004 1 (4.2) – NS – 0.8) NS 1 (4.0) – .005
2 311 (57.5) 226 (60.0) 15 (88.2) 26 (50.0) 12 (50.0) 17 (34.0) 4 (30.8) 26.7) 15 (60.0) 6 (26.1)
3 47 (8.7) 91 (24.3) 1 (5.9) 24 (46.2) 9 (37.5) 31 (62.0) 8 (61.5) 625) 5 (20.0) 15 (65.2)
NA 38 (7.1) 20 (5.3) – – 2 (8.3) 2 (4.0) 1 (7.7) 10.0) 4 (16.0) 2 (8.7)
Lymph nodes, n (%)
0 293 (54.2) 192 (50.9) NS 9 (50.0) 31 (54.4) NS 6 (25.0) 17 (34.0) NS 3 (23.1) 53.3) NS 10 (40.0) 13 (56.5) NS
1 to 3 145 (26.9) 109 (29.1) 7 (38.9) 18 (31.6) 9 (37.5) 10 (20.0) 5 (38.5) 26.7) 8 (32.0) 4 (17.4)
≥4 101 (18.7) 73 (19.5) 2 (11.1) 8 (14.0) 9 (37.5) 22 (44.0) 5 (38.5) 19.2) 6 (24.0) 4 (17.4)
NA 1 (0.2) 2 (0.5) – – – 1 (2.0) – – 1 (4.0) 2 (8.7)
Chemotherapy, n (%)
No 275 (50.8) 174 (46.1) NS 8 (44.4) 16 (28.1) NS 2 (8.3) 11 (22.0) NS 2 (15.4) 13.3) NS 7 (28.0) 7 (17.4) NS
Yes 260 (48.2) 199 (53.1) 10 (55.6) 41 (71.9) 21 (87.5) 38 (76.0) 11 (84.6) 1 (85.0) 18 (72.0) 19 (82.6)


































Table 3 Patient characteristics for breast cancer intrinsic subtypes defined by six biomarkersa (Continued)
Hormonotherapy, n (%)
No 106 (19.5) 67 (17.6) NS 4 (22.2) 13 (22.8) NS 18 (75.0) 32 (64.0) NS 9 (69.2) 86 (71.7) NS 10 (40) 14 (60.9)
Yes 432 (80.1) 307 (81.9) 14 (77.8) 44 (77.2) 6 (25.0) 18 (36.0) 4 (30.8) 34 (28.3) 15 (60) 9 (39.1)
NA 2 (0.4) 2 (0.5) – – – – – – – –
Local therapy, n (%)
Mastectomy
alone
172 (31.9) 105 (28.0) 7 (38.9) 14 (24.6) 12 (50.0) 16 (32.0) 5 (38.5) 28 (23.3) 15 (60.0) 8 (34.8)
Mastectomy + RT 61 (11.3) 36 (9.6) NS 1 (5.6) 5 (8.8) NS 6 (25.0) 11 (22.0) NS 3 (23.1) 17 (14.2) NS 4 (16.0) 6 (26.1) NS
Lumpectomy
alone
28 (5.2) 13 (3.5) 1 (5.6) 4 (7.0) – 4 (8.0) – 5 (4.2) – –
Lumpectomy +
RT
279 (51.6) 222 (58.9) 9 (50.0) 34 (59.6) 6 (25.0) 19 (38.0) 5 (38.5) 70 (58.3) 6 (24.0) 9 (39.1)
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10.7% basal-like cases and 3.9% TNP nonbasal cases.
Among patients with the various intrinsic subtypes,
there were significant differences in histological grade
depending on the proliferation rate defined by the Ki-67
index (Tables 2 and 3).
Analysis of actuarial breast cancer–free survival by
intrinsic subtype and proliferation rate
The molecular subtypes differed significantly in BCFS
when the four-biomarker definition was used (Figure 2A),
with luminal A cases exhibiting the longest survival
(P = 0.001). Analysis of BCFS in each intrinsic subtype
according to Ki-67 value revealed a significant differ-
ence in the luminal subtypes (odds ratio (OR) = 0.71,
95% CI = 0.39 to 0.93; P = 0.009 (luminal A vs. luminal B))
(Figure 2B), but not in the HER2-enriched subtype (OR =
0.63, 95% CI = 0.24 to 1.65; P = 0.1) (Figure 2C) or the
triple-negative subtype (OR = 0.96, 95% CI = 0.42 to 2.33;
P = 0.9) (Figure 2D). Similar results were obtained when




























539 505 460 374 294 208 142 Luminal A
375 337 290 208 140 86 64 Luminal B
151 123 99 80 57 42 33 HER−2
182 149 127 109 88 69 58 Triple negative
Luminal A 124 539 187.81
Luminal B 106 375 249.67
HER−2 49 151 −−−
Triple negative 65 182 −−−
Event All Median
Log−rank P = 0.001





























42 36 31 27 21 18 14 Ki−67 < 14
107 85 66 51 34 23 18 Ki−67
Ki−67 < 14 11 42 −−−
Ki−67 >= 14 38 107 −−−
Event All Median
Tarone−Ware P = 0.184
OR = 0.63 (0.24,1.65)




Figure 2 Kaplan-Meier curves for breast cancer–free survival based o
(A) Whole series according to the four intrinsic subtypes. (B) Luminal tumo
Ki-67 value. (D) Triple negative tumors according to Ki-67 value. HER2, humIn Table 4, the cumulative 3-year and 5-year BCFS
rates for the four intrinsic subtypes are listed. At 3 years,
the absolute difference in BCFS between the luminal A
and the luminal B phenotypes was 7.6%, which is com-
parable to the difference found at 5 years (8.7%). Similar
data were found regarding the luminal A and the HER2-
enriched phenotypes (19.5% and 17.1%, respectively) and
the luminal A and triple-negative phenotypes (18.3% and
17.4%, respectively). The results exhibited similar trends
when the six-marker definition was used (Table 5).
Analysis of recurrence prognostic factors and variations
in recurrence risk over time
The final model for multivariate analyses of BCFS for
patients classified using the four biomarkers revealed
that tumor size, lymph node status, type of local therapy,
use of adjuvant endocrine therapy and intrinsic subtypes
were significant independent predictors of disease recur-
rence (Table 6). The analysis of compliance with propor-
tional hazards assumptions were rejected (P < 0.0001),




























539 505 460 374 294 208 142 Ki−67 < 14
375 337 290 208 140 86 64 Ki−67
Ki−67 < 14 124 539 187.81
Ki−67 >= 14 106 375 249.67
Event All Median
Log−rank P = 0.009
OR = 0.71 (0.39,0.93)






























38 32 26 20 18 14 12 Ki−67 < 14
143 116 100 88 69 55 46 Ki−67
Ki−67 < 14 13 38 199.38
Ki−67 >= 14 51 143 −−−
Event All Median
Log−rank P = 0.964
OR = 0.99 (0.42,2.33)
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77 68 57 47 34 21 15 Luminal−HER2
74 55 42 33 23 21 18 HER2 enriched
133 108 91 80 62 49 42 Basal like
49 41 36 29 26 20 16 TN non−basal
(A) All Subtypes
Luminal A 124 539 187.81
Luminal B 106 375 249.67
Luminal−HER2 19 77 −−−
HER2 enriched 30 74 −−−
Basal like 47 133 −−−
TNP−nonbasal 18 49 199.38
Event All Median
Log−rank P < 0.0001
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375 337 290 208 140 86 64 Ki−67
(B) Luminal A + Luminal B
Ki−67 < 14 124 539 187.81
Ki−67 >= 14 106 375 249.67
Event All Median
Log−rank P = 0.009
OR = 0.71 (0.49,1.03)
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(C) Luminal−HER2T
Ki−67 < 14 3 18 −−−
Ki−67 >= 14 16 57 −−−
Event All Median
Peto−Peto P = 0.2
OR = 0.45 (0.08,2.57)






























24 20 16 14 9 9 7 Ki−67 < 14
50 35 26 19 14 12 11 Ki−67
(D) HER2 enriched
Ki−67 < 14 8 24 −−−
Ki−67 >= 14 22 50 −−−
Event All Median
Tarone−Ware P = 0.248
OR = 0.62 (0.19,2.02)






























25 20 17 12 11 8 6 Ki−67 < 14
23 20 18 16 14 12 10 Ki−67
(E) TNP non−basal
Ki−67 < 14 10 25 199.38
Ki−67 >= 14 7 23 −−−
Event All Median
Tarone−Ware P = 0.484
OR = 1.41 (0.34,5.84)






























13 12 9 8 7 6 6 Ki−67 < 14
120 96 82 72 55 43 36 Ki−67
(F) Basal like
Ki−67 < 14 3 13 −−−
Ki−67 >= 14 44 120 −−−
Event All Median
Peto−Peto P = 0.272
OR = 0.51 (0.09,2.76)
No. of patients at risk
>= 14
Figure 3 Kaplan-Meier curves for breast cancer–free survival based on intrinsic subtypes (six markers) and proliferation rate. (A) Whole
series according to six intrinsic subtypes. TNP, triple-negative phenotype. (B) Luminal tumors according to Ki-67 value. OR, odds ratio. (C) Luminal
human epidermal growth factor receptor 2 (HER2) tumors according to Ki-67 value. (D) HER2-enriched tumors according to Ki-67 value. (E) Triple-
negative-nonbasal tumors according to Ki-67 value. (F) Basal-like tumors according to Ki-67 value.
Table 4 Estimated cumulative breast cancer–free survival (four-marker definition)a
Intrinsic subtype 2-year BCFS 95% CI 3-year BCFS 95% CI 5-year BCFS 95% CI
Luminal A 96.7% 95.2% to 98.3% 92.8% 90.6% to 95.0% 85.8% 82.7% to 88.9%
Luminal B 91.5% 88.6% to 94.4% 85.2% 81.6% to 89.0% 77.1% 72.8% to 81.7%
HER2-enriched 81.2% 75.0% to 87.8% 73.3% 66.4% to 81.0% 68.7% 61.4% to 76.8%
Triple-negative 83.0% 77.7% to 88.8% 74.5% 68.3% to 81.2% 68.4% 61.8% to 75.7%
aBCFS, breast cancer–free survival; CI, confidence interval; HER2, human epidermal growth factor 2. All values are statistically significant.
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Table 5 Estimated cumulative breast cancer–free survival (six-marker definition)a
Intrinsic subtype 2-year BCFS 95% CI 3-year BCFS 95% CI 5-year BCFS 95% CI
Luminal A 96.7% 95.2% to 98.3% 92.8% 90.6% to 95.0% 85.8% 82.7% to 88.9%
Luminal B 91.5% 88.6% to 94.4% 85.2% 81.6% to 89.0% 77.1% 72.8% to 81.7%
Luminal HER2 89.2% 82.5% to 96.6% 81.0% 72.4% to 90.5% 77.1% 68.8% to 72.4%
HER2-enriched 72.4% 62.5% to 83.8% 63.9% 53.5% to 76.3% 58.3% 47.6% to 71.5%
Basal-like 80.8% 74.3% to 87.9% 72.2% 64.9% to 80.4% 68.1% 60.5% to 76.7%
TNP nonbasal 89.3% 80.9% to 98.6% 80.6% 70.0% to 92.8% 66.7% 54.2% to 82.1%
aBCFS, breast cancer–free survival; CI, confidence interval; HER2, human epidermal growth factor 2; TNP, triple-negative phenotype. All values are statistically significant.
Table 6 Final multivariate Cox analysis of breast cancer–
free survival with four-biomarker definition of intrinsic
subtypesa
Variables HR 95% CI Pb
Tumor size, cm
<2 1.0
2 to 5 1.6 1.2 to 2.1 0.0004
>5 1.9 1.2 to 3.1 0.005
Lymph nodes
0 1.0
1 to 3 1.4 1.0 to 1.8 0.01
≥4 2.8 2.1 to 3.7 <0.0001
Local therapy
Mastectomy alone 1.0
Mastectomy + RT 1.1 0.7 to 1.5 0.6
Lumpectomy alone 1.2 0.6 to 2.1 0.5
Lumpectomy + RT 0.6 0.4 to 0.8 0.0005
Endocrine therapy
Yes 1.0
No 0.7 0.5 to 0.9 0.01
Subtype
Luminal A 1.0
Luminal B 1.3 1.0 to 1.7 0.02
HER2-enriched 1.4 1.0 to 2.0 0.04
Triple-negative 1.3 0.9 to 1.8 0.09
aCI, confidence interval; HER2, human epidermal growth factor receptor 2; HR,
hazard ratio; RT, radiotherapy. bAll likelihood ratio, Wald and logrank statistical
tests were two-sided.
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http://breast-cancer-research.com/content/15/5/R98over time. To further explore this issue, an analysis of
the hazards function according to the intrinsic subtypes
was performed, and the resulting smoothed curves are
shown in Figure 4. We also investigated whether these
patterns of relapse differed regarding the proliferation
rate. The luminal A cases, with Ki-67 <14%, had a pro-
gressive increased risk that approached 0.3% (95% CI =
0.2% to 0.4%) at 39.4 months, with the curve remaining
nearly steady during the rest of follow-up (Figure 4B).
However, luminal B patients, with Ki-67 ≥14%, displayed
a different pattern of recurrence. A maximum risk of 0.5%
(95% CI = 0.4% to 0.6%) was reached at 33.8 months, and
a second peak of late recurrence risk (0.3%; 95% CI = 0.2%
to 0.5%) appeared at 112 months (Figure 4B). For the
HER2-enriched subtype, the first peak occurred at ap-
proximately the same time, nearly 20 months for both
groups, but the maximum risk was 1.0% (95% CI = 0.5%
to 2%) in patients with Ki-67 <14% and a maximum
risk of 1.3% (95% CI = 0.9% to 3.1%) in those cases with
Ki-67 ≥14%. A second risk peak at 72 months appeared
for both HER2 populations, but, interestingly, the mag-
nitude in this case seems to be higher in the HER2-
enriched group with Ki-67 <14% (0.75% risk; 95% CI =
0.3% to 1.8%) than with Ki-67 ≥14% (0.25% risk; 95%
CI = 0.08% to 2.7%) (Figure 4C). Triple-negative cases
with low Ki-67 exhibited a smooth curve. After a max-
imum risk of 0.7% (95% CI: 0.4% to 1.7%) reached at
32.6 months, the curve remained nearly steady until
52 months, at which point it started to decline. The
maximum recurrence risk for triple-negative and high
Ki-67 patients was reached at 17.7 months (0.9% risk;
95% CI = 0.6% to 1.1%), decreased to 0.3% by 48 months
(95% CI = 0.2% to 0.5%) and was minimal at 80 months
(0.04% risk; 95% CI = 0.007% to 0.2%) (Figure 4D).
The recurrence hazard rates for the intrinsic subtypes
at different time points are listed in Table 7, showing
their respective hazard ratios and considering luminal A
as the reference value. It is noteworthy that the informa-
tion is quite different from data derived from actuarial
BCFS, in which the absolute differences between each
intrinsic subtype and luminal A were comparable at two
time points: 36 and 60 months. The initial risk for
luminal B is about twice that for luminal A, and, after36 months, this risk decreases slowly. After the eighth
year, however, the recurrence risk for luminal B in-
creases to more than twice that of luminal A. For HER2-
enriched patients, the risk is nearly fivefold that of lu-
minal A during the first 2 years and double at 36 months.
Between the fourth and the fifth years after surgery,
however, the recurrence risk for HER2-enriched patients
is lower than that for luminal A patients. After that time,
the recurrence risk for HER2-enriched patients in-
creases, becoming more than twice that of luminal A.
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Ki−67 < 14 0.3% 39.4
Ki−67 >= 14 0.5% 33.8
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Ki−67 < 14 1% 22
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Ki−67 < 14 0.7% 32.6
Ki−67 >= 14 0.9% 17.7
Total 0.8% 20








Figure 4 Recurrence hazard rate functions for intrinsic subtypes (four markers) and proliferation rate. (A) Whole series according to Ki-67
value. (B) Luminal tumors as a whole and according to Ki-67 value. (C) Human epidermal growth factor 2 (HER2)-enriched tumors as a whole and
according to Ki-67 value. (D) Triple-negative tumors as a whole and according to Ki-67 value. max(HR), maximum hazard rate.
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http://breast-cancer-research.com/content/15/5/R98times higher than that for luminal A during the first
2 years and nearly double at 36 months; however, at
60 months, the recurrence risk is similar between the
two subtypes.
Similar results were obtained when multivariate ana-
lysis was performed with intrinsic subgroup populations
defined by the six biomarkers (Table 8). In the same
way, each intrinsic subtype displayed a specific pattern
of recurrence over time, although the analysis based on
the Ki-67 value was not performed, owing to the size of
the subgroups, which were too small to make estimates
realistic (Figure 5 and Table 9).
Discussion
Our work highlights the importance of the proliferation
pathway in the prognosis of early breast cancer intrinsic
subtypes through the analysis of patient outcomes in dif-
ferent and complementary ways.
On the basis of genomics-defined luminal tumors, it
has been possible to establish a value of Ki-67 withprognostic utility usefulness in distinguishing luminal tu-
mors A and B [12]. Moreover, several studies have con-
firmed the prognostic usefulness of these intrinsic
subtypes defined by four immunohistochemical markers
[6-10] or six immunohistochemical markers [8,13-15].
However, the value of Ki-67 as a prognostic marker in
the other intrinsic subtypes, such as triple-negative and
HER2-enriched, is not clear. In our study, only the lu-
minal population demonstrated significant differences in
actuarial BCFS according to Ki-67 value. No significant
differences were found in triple-negative and HER2-
enriched tumors. It is possible that these findings are
based on our use of a Ki-67 cutoff obtained in luminal
tumors. Nevertheless, Aleskandarany et al. also failed to
detect a significant difference in actuarial survival, des-
pite using different cutoffs defined specifically for both
triple-negative and HER2-enriched tumors [31].
To improve the results obtained using adjuvant ther-
apy in breast cancer, it is important to develop methods
for accurately determining which patients need some











2 0.26 (0.2 to 0.3) 1 0.50 (0.4 to 0.6) 1.9 1.26 (0.8 to 2.0) 4.8 0.78 (0.6 to 1.0) 3.0
3 0.32 (0.2 to 0.4) 1 0.54 (0.4 to 0.6) 1.7 0.63 (0.3 to 1.3) 2.0 0.60 (0.4 to 0.8) 1.9
4 0.33 (0.2 to 0.4) 1 0.43 (0.3 to 0.5) 1.3 0.28 (0.1 to 0.9) 0.8 0.39 (0.2 to 0.5) 1.2
5 0.30 (0.2 to .04) 1 0.29 (0.2 to 0.4) 1.0 0.14 (.02 to 1.0) 0.4 0.24 (0.1 to 0.4) 0.8
6 0.23 (0.1 to 0.3) 1 0.26 (0.2 to 0.5) 1.1 0.62 (0.2 to 1.7) 2.6 0.17 (.06 to 0.3) 0.7
7 0.23 (0.1 to 0.3) 1 0.31 (0.2 to 0.6) 1.4 NA NA 0.11 (.04 to 0.3) 0.5
8 0.17 (0.1 to 0.2) 1 0.35 (0.2 to 0.7) 2.0 NA NA 0.11 (.04 to 0.3) 0.6
9 0.15 (0.1 to 0.3) 1 0.38 (0.2 to 0.7) 2.5 NA NA 0.10 (.03 to 0.3) 0.7
10 0.19 (0.1 to 0.4) 1 0.28 (0.1 to 0.6) 1.5 NA NA 0.16 (.06 to 0.4) 0.8
aHR, hazard ratio; HER2, human epidermal growth factor receptor 2; NA, not available. bReference value. Note: 95% confidence intervals are presented
in parentheses.
Table 8 Final multivariate Cox analysis of breast cancer–
free survival with six-biomarker definition of intrinsic
subtypesa
Variable HR 95% CI Pb
Tumor size, cm
<2 1.0
2 to 5 1.6 1.2 to 2.1 0.0003
>5 2.0 1.2 to 3.2 0.005
Lymph nodes
0 1.0
1 to 3 1.4 1.0 to 1.8 0.01
≥4 2.8 2.1 to 3.7 <0.0001
Local therapy
Mastectomy alone 1.0
Mastectomy + RT 1.1 0.8 to 1.5 0.6
Lumpectomy alone 1.2 0.7 to 2.1 0.5
Lumpectomy + RT 0.6 0.5 to 0.8 0.0009
Hormonotherapy
Yes 1.0
No 0.7 0.5 to 0.9 0.01
Subtype
Luminal A 1.0
Luminal B 1.4 1.1 to 1.7 0.02
Luminal HER2 1.4 0.8 to 2.2 0.2
HER2-enriched 1.5 0.9 to 2.2 0.08
Basal-like 1.2 0.8 to 1.8 0.3
TNP nonbasal 1.6 0.9 to 2.6 0.06
aCI, confidence interval; HR, hazard ratio; HER2, human epidermal growth factor
receptor 2; RT, radiotherapy; TNP, triple-negative phenotype. bAll likelihood ratio,
Wald and logrank statistical tests were two-sided.
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http://breast-cancer-research.com/content/15/5/R98kind of treatment. Furthermore, it is necessary to estab-
lish the best treatment option for each patient and the
best timing of treatment administration, because previ-
ous studies have shown that there are significant differ-
ences in the timing of disease recurrence, depending on
tumor characteristics. Using a cumulative survival meth-
odology, researchers in various studies have found that,
in triple-negative and HER2 phenotypes, most relapses
occur during the first 3 years of follow-up, whereas in
the luminal subtypes, a significant number of recur-
rences occur in subsequent years [32-38]. Nevertheless,
the use of the hazard function analysis methodology de-
fines, in much greater detail, the changes in the risk of
relapse over time, highlighting when a recurrence occurs
rather than simply calculating the overall recurrence
risk. In our Kaplan-Meier data, there were no appre-
ciable absolute differences in 3-year and 5-year BCFS be-
tween luminal A and luminal B cases (7.6% and 8.7%,
respectively), luminal A and HER2-enriched cases (19.5%
and 17.1%, respectively) or luminal A and triple-negative
cases (18.3% and 17.4%, respectively). However, the hazard
function analysis detected noteworthy differences in the
relapse risk between these subgroups at the same time
points. Luminal B patients had about twice the recurrence
risk of luminal A patients 3 years after surgery, whereas
the hazard ratio was only 1.0 at 5 years. In HER2-enriched
tumors, the recurrence hazard ratio in comparison with
luminal A was 2.0 at 3 years and 0.4 at 5 years postsur-
gery. Also, triple-negative patients had different recur-
rence risks when luminal A data were considered as
reference values (1.9 at 3 years and 0.8 at 5 years).
A visual inspection of the recurrence hazard curves
presented herein shows that each intrinsic subtype has a
particular pattern of relapse over time. More import-
antly, these patterns change depending on the level of
activation of the proliferation pathway as determined by
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t = 35.4 months
Figure 5 Recurrence hazard rate functions for intrinsic subtypes (six markers). (A) Luminal A tumors. (B) Luminal B tumors. (C) Luminal
human epidermal growth factor receptor 2 (HER2) tumors. (D) HER2-enriched tumors. (E) Triple-negative phenotype (TNP) nonbasal tumors.
(F) Basal-like tumors. max(HR), maximum hazard rate.
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http://breast-cancer-research.com/content/15/5/R98pattern of recurrence in the various intrinsic subtypes,
and the results of these studies have demonstrated haz-
ard function curves similar to ours. Greater short-term
risk between 1 and 3 years after surgery was observed in
the triple-negative tumors [34,38-42], HER2-enriched tu-
mors [38,40,42] and luminal B tumors [40,42], whereas
the long-term risk was greater in the luminal subtypes
[38,40,42]. Interestingly, a second peak of late recur-
rences was also observed in the HER2 phenotypes
[38,42]. No data regarding differences that depend onthe Ki-67 value are available, except those reported by
Keam et al. [41]. Those authors analyzed a series of 109
triple-negative patients and used a Ki-67 cutoff of 10.
Similar to our results, the low Ki-67 group showed a
steady pattern and the high Ki-67 group displayed a
sharp recurrence peak at 12 months.
The first peak of early relapses has been associated
with surgery because the removal of the primary tumor
could trigger the growth of clinically unapparent dor-
mant micrometastatic foci [43]. Surgery could promote

















2 0.24 (0.2 to 0.3) 1 0.50 (0.4 to 0.6) 2.05 0.56 (0.3 to 0.9) 2.30 1.83 (1.1 to 3.1) 7.53 0.84 (0.6 to 1.2) 3.46 0.60 (0.3 to 1.1) 2.46
3 0.32 (0.2 to 0.4) 1 0.54 (0.4 to 0.6) 1.68 0.46 (0.2 to 0.8) 1.43 0.45 (0.1 to 1.4) 1.41 0.58 (0.4 to 0.8) 1.83 0.66 (0.4 to 1.1) 2.06
4 0.33 (0.2 to 0.4) 1 0.43 (0.3 to 0.5) 1.32 0.27 (0.1 to 0.5) 0.82 0.41 (0.1 to 1.6) 1.27 0.29 (0.2 to 0.5) 0.90 0.60 (0.3 to 1.1) 1.84
5 0.29 (0.2 to 0.3) 1 0.29 (0.2 to 0.4) 1.00 0.20 (0.07 to 0.5) 0.68 0.32 (0.06 to 1.6) 1.09 0.14 (0.05 to 0.3) 0.47 0.51 (0.3 to 1.0) 1.75
6 0.26 (0.1 to 0.3) 1 0.26 (0.1 to 0.4) 1.02 0.19 (0.05 to 0.6) 0.72 0.55 (0.1 to 2.2) 2.12 0.08 (0.03 to 0.2) 0.29 0.39 (0.2 to 0.9) 1.51
7 0.21 (0.1 to 0.3) 1 0.31 (0.2 to 0.5) 1.43 0.13 (0.03 to 0.5) 0.59 NA NA 0.05 (0.01 to 0.3) 0.24 0.25 (0.08 to 0.8) 1.16
8 0.18 (0.1 to 0.2) 1 0.35 (0.2 to 0.6) 1.95 0.01 (0.00 to 0.04) 0.06 NA NA 0.09 (0.02 to 0.3) 0.49 0.15 (0.04 to 0.6) 0.86
9 0.16 (0.1 to 0.3) 1 0.38 (0.2 to 0.7) 2.33 NA NA NA NA 0.14 (0.04 to 0.4) 0.84 0.05 (0.01 to 0.2) 0.30
10 0.21 (0.1 to 0.3) 1 0.28 (0.1 to 0.6) 1.33 NA NA NA NA 0.21 (0.08 to 0.6) 1.00 NA NA
aHER2, human epidermal growth factor receptor 2; HR, hazard ratio; NA, not available; TNP, triple-negative phenotype. bReference value. Note: 95% confidence
interval is represented between the parentheses.
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http://breast-cancer-research.com/content/15/5/R98the growth of micrometastatic disease through several
processes, such as an alteration in the angiogenic bal-
ance [43,44], surgical stress-induced neuroendocrine ac-
tivation [45] or alteration of the immune response
[46,47]. These mechanisms could influence particularly
the disease course in intrinsic subtypes with high expres-
sion of proliferation pathways, such as HER2 or basal-
like tumors. An increase of proliferation has been re-
ported in HER2-positive patients with positive tumor
margins after conservative surgery between the first and
second tumor samples, as determined using Ki-67 im-
munohistochemistry, but this was not the case with
HER2-negative cases [48].
The information provided by the study of the patterns
of recurrence in early breast cancer would benefit pa-
tients in different ways. In this regard, our results could
generate several hypotheses that, if confirmed in pro-
spective randomized trials, would have noteworthy prac-
tical value. First of all, the surveillance after initial
treatment could be fit to the expected recurrence pat-
tern based on each intrinsic subtype. More important,
however, is that the adjuvant treatment could be tailored
more accurately according to each intrinsic subtype. Pa-
tients with tumors with high proliferation rates, such as
HER2-enriched or basal-like, would benefit from more
aggressive chemotherapy schedules (for example, dose-
dense). Such types of chemotherapy could avoid some of
the recurrences that appear during the first peak. Also,
in these cases with high expression of proliferation path-
ways, treatment with novel inhibitors of the cell cycle
(for example, palbociclib) could be especially useful. In
addition, those patients with luminal HER2 subtype
could benefit from a second treatment with trastuzumab
to decrease the second peak of recurrence.
The essential strengths of our study are the detailed
and careful analysis of BCFS data, which describes aspecific relapse pattern for every intrinsic subtype as a
whole and is distinguished by the level of proliferation
pathway activation in a homogeneously managed series
of patients representing a full spectrum of breast can-
cers, which is not always available in clinical trial–based
samples. The main limitation of our study is the lack of
availability of tumor samples from all patients. It could
be argued that the use of different schemes of adjuvant
chemotherapy could have caused less consistency in our
results. Evidence from the studies that initially described
the special recurrence pattern of early breast cancer sug-
gest that the structure of this pattern is the same, re-
gardless of the type of adjuvant therapy used [16-18]. In
this regard, the only change we observed was the height
of the recurrence peaks, but not their number or their
shape. Data from a patient series in Milan, Italy [17,18],
and from Eastern Cooperative Oncology Group coordinated
studies [16], including patients treated only with surgery
and patients treated with surgery plus several schemes of
adjuvant chemotherapy, reproduced this recurrence struc-
ture with robustness.
The proliferation pathway plays a key role in the de-
velopment of early recurrence after surgery in breast
cancer, regardless of the intrinsic subtype involved.
This conclusion is reinforced by the fact that our data
were obtained by following a different statistical ap-
proach to survival analyses. Our results need to be cor-
roborated in larger series of patients treated with
current adjuvant systemic therapies; however, transfer-
ring knowledge regarding temporary patterns of recur-
rence in the development and design of future clinical
trials in the adjuvant setting could be considered in es-
tablishing the timing or schedule of treatment adminis-
tration that would be more effective. In addition, our
data could have some impact on recommendations
concerning patient follow-up.
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Breast cancer intrinsic subtypes using both four- and six-
marker immunohistochemical panels and proliferation
assessed by using Ki-67 were determined in a large and
homogeneous cohort of patients collected prospectively.
Our most important findings are that each intrinsic sub-
type displayed a specific pattern of recurrence and that the
proliferation pathway played a key role in the development
of early recurrence. These results point directly to adjuvant
treatment approaches and clinical follow-up schedules for
surveillance, suggesting that both should be different, de-
pending on intrinsic subtype. Moreover, understanding of
these distinct clinical patterns of relapse may lead to new
biological insights into the development and management
of breast cancer.
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